With offices in Toronto, Canada and Bogotá, Colombia, Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC) announced today that its Zerenia clinical subsidiary has signed a contract with Capital Salud EPS to provide medical cannabis and services to patients of the EPS.
In Colombia, EPS (Healthcare Providing Entities) function similar to PPO or HMO health networks, administrating health care between IPS (Healthcare Providing Institutions) units such as hospitals and clinics, and healthcare consumers, which choose from a selection of EPS providers. Some are private companies, others, such as Capital Salúd is owned by the city of Bogotá.
Under the new agreement, Zerenia will provide integrative health services and medical cannabis products to patients diagnosed with chronic pain, mental health, neurological conditions, and epilepsy, amongst others. Capital Salud serves 1.2 million individuals, including approximately 280,000 patients diagnosed with chronic conditions.
Zerenia has already begun treating Capital Salud patients.
“This agreement by Capital Salud EPS seeks the materialization of Agreement 831 that we promoted at the Bogota City Council, with the objective of making Bogota the medical cannabis hub of the country,” said Bogotá city council member Juan Baena.
“The city of Bogota has embraced medical cannabis as a catalyst for social and economic growth. We are honored that Zerenia was selected by CAPITAL SALUD EPS to provide medical cannabis services and products to their patients. Over the past 2 years, Zerenia has invested in expanding its clinic locations across the city, generating proprietary scientific evidence on the benefits of medical cannabis, and delivering superior patient service quality to become the leaders in medical cannabis in Colombia, Latin America and Europe,” said Khiron CEO and co-founder Álvaro Torres.
“We are thankful for the confidence placed by CAPITAL SALUD on Zerenia, and with an installed capacity of over 300,000 annual consultations, we are more than prepared to service their patient base. We are convinced that we have created a unique medical cannabis platform that other insurance companies in Colombia and abroad will want to offer to their patients to improve their quality of life,” he continued.